Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OMB Grants CFSAN Green Light For Qualified Health Claim Study

This article was originally published in The Tan Sheet

Executive Summary

CFSAN is refining its approach to report card schemes as well as other ways of communicating qualified health claims (QHCs) in a proposed study approved by OMB Nov. 29

You may also be interested in...



FDA Looms Large As Bayer Surrenders One A Day Selenium Prostate Claims

Bayer seems to be heeding FDA's message that the administration will not tolerate playing fast and loose with health claims

FDA Looms Large As Bayer Surrenders One A Day Selenium Prostate Claims

Bayer seems to be heeding FDA's message that the administration will not tolerate playing fast and loose with health claims

FDA Looms Large As Bayer Surrenders One A Day Selenium Prostate Claims

Bayer seems to be heeding FDA's message that the administration will not tolerate playing fast and loose with health claims

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel